⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for enasidenib

Every month we try and update this database with for enasidenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionNCT05010772
Acute Myeloid L...
Decitabine and ...
Enasidenib
Gilteritinib
Ivosidenib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 MutationNCT04203316
Recurrent Acute...
Refractory Acut...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Enasidenib
Enasidenib Mesy...
24 Months - 21 YearsChildren's Oncology Group
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative NeoplasmsNCT04955938
IDH Mutation
IDH1 Mutation
IDH2 Gene Mutat...
Blood Cancer
Myeloproliferat...
Ivosidenib
Enasidenib
Fedratinib
18 Years - University of Chicago
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationNCT02577406
Leukemia, Myelo...
Isocitrate Dehy...
AG-221
BSC
Azacitidine
Low-dose cytara...
Intermediate-do...
60 Years - Celgene
A Study of Enasidenib in People With Clonal Cytopenia of Undetermined SignificanceNCT05102370
Clonal Cytopeni...
CCUS Clonal Cyt...
Enasidenib
18 Years - Memorial Sloan Kettering Cancer Center
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromeNCT03383575
Acute Myeloid L...
Blasts 20-30 Pe...
Chronic Myelomo...
IDH2 Gene Mutat...
Myelodysplastic...
Recurrent High ...
Refractory High...
Azacitidine
Enasidenib
Quality-of-Life...
12 Years - M.D. Anderson Cancer Center
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative NeoplasmsNCT04955938
IDH Mutation
IDH1 Mutation
IDH2 Gene Mutat...
Blood Cancer
Myeloproliferat...
Ivosidenib
Enasidenib
Fedratinib
18 Years - University of Chicago
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 MutationNCT04203316
Recurrent Acute...
Refractory Acut...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Enasidenib
Enasidenib Mesy...
24 Months - 21 YearsChildren's Oncology Group
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaNCT04774393
Acute Myeloid L...
Recurrent Acute...
Refractory Acut...
Decitabine and ...
Enasidenib
Ivosidenib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionNCT05010772
Acute Myeloid L...
Decitabine and ...
Enasidenib
Gilteritinib
Ivosidenib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsNCT06176989
Metastatic Chon...
Locally Advance...
Metastatic Sino...
Locally Advance...
Metastatic Larg...
Locally Advance...
Metastatic Olfa...
Locally Advance...
Metastatic Sino...
Locally Advance...
Enasidenib
18 Years - 120 YearsNational Institutes of Health Clinical Center (CC)
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative NeoplasmsNCT04955938
IDH Mutation
IDH1 Mutation
IDH2 Gene Mutat...
Blood Cancer
Myeloproliferat...
Ivosidenib
Enasidenib
Fedratinib
18 Years - University of Chicago
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionNCT05010772
Acute Myeloid L...
Decitabine and ...
Enasidenib
Gilteritinib
Ivosidenib
Venetoclax
18 Years - M.D. Anderson Cancer Center
A Study of Enasidenib in People With Clonal Cytopenia of Undetermined SignificanceNCT05102370
Clonal Cytopeni...
CCUS Clonal Cyt...
Enasidenib
18 Years - Memorial Sloan Kettering Cancer Center
A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid LeukemiaNCT04075747
Acute Myeloid L...
CPX-351
Venetoclax
Midostaurin
Enasidenib
18 Years - 75 YearsJazz Pharmaceuticals
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsNCT06176989
Metastatic Chon...
Locally Advance...
Metastatic Sino...
Locally Advance...
Metastatic Larg...
Locally Advance...
Metastatic Olfa...
Locally Advance...
Metastatic Sino...
Locally Advance...
Enasidenib
18 Years - 120 YearsNational Institutes of Health Clinical Center (CC)
A Study of Perpetrator Drug Interactions of Enasidenib in AML PatientsNCT03720366
Leukemia, Myelo...
enasidenib
Arm 1 probes
Arm 2 Probes
Arm 3 probes
18 Years - Celgene
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood CancersNCT04092179
Acute Myeloid L...
Relapsed Cancer
Refractory Canc...
IDH2 Gene Mutat...
Enasidenib
Venetoclax
18 Years - University Health Network, Toronto
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: